Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nang Kuang Pharmaceutical CoTPE:1752 -1.10%88 EBITDA Margin % is 23.89% as of Dec. 2025, which is 2% above its 10-year median of 23.52. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 79.56% on this metric.
Nang Kuang Pharmaceutical Co (TPE:1752) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nang Kuang Pharmaceutical Co EBITDA Margin % Related Terms
Nang Kuang Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co EBITDA Margin % Chart
TPE:1752 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co (TPE:1752) has a EBITDA Margin % of 23.89% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nang Kuang Pharmaceutical Co and its competitors. This is near median its historical median of 23.52. Over the past decade, Nang Kuang Pharmaceutical Co's EBITDA Margin % has ranged from 18.73 to 30.49. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #167 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 20.4%.
Is Nang Kuang Pharmaceutical Co's EBITDA Margin % too high?
Nang Kuang Pharmaceutical Co's current EBITDA Margin % of 23.89% is near median its 10-year median of 23.52. Over the past 10 years, this metric has ranged from a low of 18.73 to a high of 30.49. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Nang Kuang Pharmaceutical Co's value of 23.89% is 221.1% above this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #167 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #167 out of 817 companies for EBITDA Margin %. This places Nang Kuang Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.44. Nang Kuang Pharmaceutical Co's value of 23.89% is 221.1% above this benchmark. Historically, Nang Kuang Pharmaceutical Co's own EBITDA Margin % has ranged from 18.73 to 30.49 over the past decade. While the company's 10-year median is 23.52 vs. the industry median of 7.44, Nang Kuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current EBITDA Margin % of 23.89% is 221.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nang Kuang Pharmaceutical Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current EBITDA Margin % is 23.89%, which is near median its own 10-year median of 23.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current EBITDA Margin % is 23.89%, which is near median its 10-year median of 23.52 and 221.1% above the Medical Devices & Instruments industry median of 7.44. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current EBITDA Margin % is 23.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TPE:1752:
EBITDA Margin %: 23.89% (near median its 10-year median of 23.52)
GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
Industry Position: 221.1% above the Medical Devices & Instruments median (#167 of 817)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score
Get the complete analysis for TPE:1752
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
